• National Institute for Health and Clinical Excellence (NICE). Adalimumab for the treatment of psoriatic arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Aug. 26 p. (Technology appraisal guidance; no. 125).

This is the current release of the guideline.

Adalimumab, within its licensed indication, is recommended as an option for the treatment of adults with active and progressive psoriatic arthritis only when the following criteria are met.

• The person has peripheral arthritis with three or more tender joints and three or more swollen joints.
• The psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying anti-rheumatic drugs (DMARDs), administered either individually or in combination.

Adalimumab treatment should be discontinued after 12 weeks in adults whose psoriatic arthritis has not shown an adequate response when assessed using the psoriatic arthritis response criteria (PsARC). For the purposes of this guidance, an adequate response is defined as:

• An improvement in at least two of the four PsARC criteria, one of which has to be joint tenderness or swelling score, with no worsening in any of the four criteria.

It is recommended that the use of adalimumab for the treatment of psoriatic arthritis in adults should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of psoriatic arthritis.

None provided

The type of evidence supporting the recommendations is not specifically stated.

• National Institute for Health and Clinical Excellence (NICE). Adalimumab for the treatment of psoriatic arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Aug. 26 p. (Technology appraisal guidance; no. 125).

Not applicable: The guideline was not adapted from another source.

2007 Aug

National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]

National Institute for Health and Clinical Excellence (NICE)

Appraisal Committee

Committee Members: Professor David Barnett Professor of Clinical Pharmacology, University of Leicester; Dr David W Black Director of Public Health, Derbyshire County PCT; Mr Brian Buckley Chairman, Incontact; Dr Carol Campbell Senior Lecturer, University of Teesside; Professor Mike Campbell Professor of Medical Statistics, University of Sheffield; Professor David Chadwick Professor of Neurology, Liverpool University; Mr Richard Devereaux-Phillips Public Affairs Manager, Medtronic; Professor Rachel A Elliott Lord Trent Professor of Medicines and Health, Nottingham University; Mrs Eleanor Grey Lay member; Dr Peter Jackson Clinical Pharmacologist, University of Sheffield; Professor Peter Jones Pro Vice Chancellor for Research & Enterprise, Professor of Statistics, Keele University; Ms Rachel Lewis Practice Development Facilitator, Manchester PCT; Damien Longson Consultant in Liaison Psychiatry, North Manchester General Hospital; Professor Jonathan Michaels Professor of Vascular Surgery, University of Sheffield; Dr Eugene Milne Deputy Medical Director, North East Strategic Health Authority; Dr Simon Mitchell Consultant Neonatal Paediatrician, St Mary's Hospital, Manchester; Dr Katherine Payne Health Economics Research Fellow, University of Manchester; Dr Martin J Price Head of Outcomes Research, Janssen-Cilag; Professor Andrew Stevens Chair of Appraisal Committee C; Dr Cathryn Thomas Senior Lecturer, University of Birmingham

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

This is the current release of the guideline.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.